JPRN-UMIN000030864
Recruiting
N/A
A prospective study of salvage radiotherapy combined with horrmone therapy for high-risk recurrent prostate cancer after radical prostatectomy - The SAHOP study
Department of Urology, Nara Medical University0 sites100 target enrollmentApril 1, 2018
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Recurrent prostate cancer after radical prostatectomy
- Sponsor
- Department of Urology, Nara Medical University
- Enrollment
- 100
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Inappropriate for the enrolment by the judgement of the physician
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 2
A phase II study of combination of radiotherapy and Atezolizumab/nab-paclitaxel for inoperable or recurrent PD-L1 positive triple negative breast cancerinoperable or recurrent PD-L1 positive triple negative breast cancerJPRN-jRCTs021210010Suzuki Yoshiyuki20
Recruiting
N/A
Prospective observational study of radiotherapy with respiratory migration countermeasures for breast cancerJPRN-UMIN000045576Kagawa University Hospital30
Recruiting
Phase 1
A confirmatory trial on concomitant radiotherapy and transcatheter arterial embolization to reduce skeletal-related events (SRE) related to bone metastasis from renal cell carcinoma.Bone metastasis from renal cell carcinomarenal cell carcinoma, skeletal-related eventsJPRN-jRCT1071210107Joichi Heianna52
Completed
N/A
Phase I trial evaluating combined radiotherapy with Panitumumab (Vectibix®) in patients with muscle invasive transitional cell carcinoma of the bladderbladder cancerBladder carcinoma10004994NL-OMON34833Antoni van Leeuwenhoek Ziekenhuis31
Completed
Phase 2
Phase II study of palliative radiotherapy combined with Zoledronic Acid Hydrate for metastatic bone tumor from renal cell carcinomaRenal cancerJPRN-UMIN000007836Shizuoka Cancer Center Japanese Radiation Oncology Study Group30